Marsida Saraci
@Alphabet Inc.
Latest period2024 - Q3ReportedManaged Assets$1.842BTotal holdings42
Assets growth rate-6.69%Assets growth rate (2-Q avg)-14.07%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Alphabet Inc.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 42 positions.
Assets under management
The assets under management (AUM) of Alphabet Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.842B in assets, with a quarterly growth rate of -6.69% and a 2-quarter average growth rate of -14.07%. The portfolio is managed by Marsida Saraci, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
PRMEPrime Medicine Inc
| 3.17% | $58.292M 15.062M shares@ $3.87 avg price | |
SNOWSnowflake Inc
| 0.72% | $13.158M 114,554 shares@ $114.86 avg price | Decreased -78.61% |
SANASana Biotechnology Inc
| 0.64% | $11.7M 2.812M shares@ $4.16 avg price | |
RLAYRelay Therapeutics Inc
| 0.61% | $11.107M 1.569M shares@ $7.08 avg price | |
VERAVera Therapeutics Inc
| 0.58% | $10.664M 241,264 shares@ $44.21 avg price | |
OSCROscar Health Inc
| 0.56% | $10.223M 481,988 shares@ $21.21 avg price | |
LYELLyell Immunopharma Inc
| 0.44% | $8.094M 5.865M shares@ $1.39 avg price | |
BEAMBeam Therapeutics Inc
| 0.43% | $7.879M 321,604 shares@ $24.5 avg price | |
GLUEMonte Rosa Therapeutics Inc
| 0.43% | $7.759M 1.464M shares@ $5.31 avg price | |
DNTHDianthus Therapeutics Inc
| 0.32% | $5.714M 208,697 shares@ $27.39 avg price |